Chimeric Antigen Receptor-Modified T Cells for Breast Cancer

NCT02547961 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Project terminated due to revision of local regulations

Conditions

Breast Cancer

Interventions

BIOLOGICAL: HER-2-targeting CAR T Cells infusion

Sponsor

Fuda Cancer Hospital, Guangzhou